Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment
11:45am, Wednesday, 02'nd Jul 2025
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
US FDA approves Regeneron's blood cancer therapy
11:11am, Wednesday, 02'nd Jul 2025
The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Wednesday, 02'nd Jul 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
04:05pm, Thursday, 26'th Jun 2025
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday,
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
09:19am, Wednesday, 25'th Jun 2025
Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robu
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
07:30am, Tuesday, 24'th Jun 2025
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications Initiative aims to expand and encourage philanthropy to help patients with retinal
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
06:10pm, Monday, 23'rd Jun 2025
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
10:51am, Friday, 20'th Jun 2025
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the drug.
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
02:01am, Friday, 20'th Jun 2025
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
01:00am, Friday, 20'th Jun 2025
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
01:00am, Friday, 20'th Jun 2025
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer
05:23pm, Monday, 16'th Jun 2025
Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.
Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron
07:06am, Monday, 16'th Jun 2025
Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second auction.
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints
